SUFLAVE
These highlights do not include all the information needed to use SUFLAVE safely and effectively. See full prescribing information for SUFLAVE. SUFLAVE (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution) Initial U.S. Approval: 2023
Approved
Approval ID
546cfc44-791c-4524-99a9-6a0af96c4ec8
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Jun 15, 2023
Manufacturers
FDA
Braintree Laboratories, Inc.
DUNS: 107904591
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code52268-550
Application NumberNDA215344
Product Classification
M
Marketing Category
C73594
G
Generic Name
polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution
Product Specifications
Effective DateJune 15, 2023
FDA Product Classification